{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:58:51Z","timestamp":1790416731711,"version":"4.1.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The RAVE (Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis) and RITUXIVAS (Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis) trials established rituximab (RTX) therapy in antineutrophil cytoplasmic antibody\u2013associated vasculitis (AAV). However, RAVE excluded patients with severe renal involvement (creatinine &amp;gt;354\u00a0\u00b5mol\/L). Whilst RITUXIVAS did not, treatment included RTX with two cyclophosphamide (CYC) pulses. This study reports outcomes in AAV patients with severe renal involvement treated with RTX alone compared with CYC, together with high-dose steroids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were collected retrospectively for all consecutive AAV presentations with severe renal involvement (peak creatinine &amp;gt;354\u00a0\u00b5mol\/L) between 2010 and 2023 from two renal units. The primary outcome was sustained remission with independent renal function at 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Amongst 107 de novo AAV patients, 66 received pulsed CYC with steroids [39 received plasma exchange (PLEX)], and 41 received RTX with steroids (7 received PLEX). At presentation, there was no significant difference in renal replacement therapy requirement (CYC 56% vs RTX 71%; P\u00a0=\u00a0.129), peak creatinine (511 vs 538\u00a0\u00b5mol\/L; P\u00a0=\u00a0.399) or estimated glomerular filtration rate (eGFR) (9 vs 7\u00a0mL\/min\/1.73 m2; P\u00a0=\u00a0.372). Fifty-two percent of CYC patients and 49% of RTX patients met the primary outcome (P\u00a0=\u00a0.783). At 12\u00a0months, there was no significant difference in the proportion of patients with independent renal function (CYC 65% vs RTX 56%; P\u00a0=\u00a0.582), eGFR was similar between CYC and RTX patients (28 vs 31\u00a0mL\/min\/1.73 m2; P\u00a0=\u00a0.439), and 94% of the CYC cohort were alive compared with 83% of the RTX cohort (P\u00a0=\u00a0.068).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>RTX with steroids is comparable to CYC with steroids for successfully inducing remission in AAV with severe renal involvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfag290","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:01:26Z","timestamp":1788440486000},"source":"Crossref","is-referenced-by-count":0,"title":["Rituximab therapy achieves comparable remission to cyclophosphamide in ANCA-associated vasculitis with severe kidney involvement"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6617-9969","authenticated-orcid":false,"given":"Nishant","family":"Chaudhari","sequence":"first","affiliation":[{"name":"Renal Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azm","family":"Ul\u00a0Hussain","sequence":"additional","affiliation":[{"name":"Renal Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust , Birmingham ,","place":["UK"]},{"name":"Department of Immunology and Immunotherapy, College of Medicine and Health, University of Birmingham , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Quill","sequence":"additional","affiliation":[{"name":"Renal Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Harridine","sequence":"additional","affiliation":[{"name":"Renal Unit, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashif","family":"Eqbal","sequence":"additional","affiliation":[{"name":"Renal Unit, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1343-9234","authenticated-orcid":false,"given":"Lorraine","family":"Harper","sequence":"additional","affiliation":[{"name":"Renal Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust , Birmingham ,","place":["UK"]},{"name":"Department of Applied Health Sciences, College of Medicine and Health, University of Birmingham , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Chanouzas","sequence":"additional","affiliation":[{"name":"Renal Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust , Birmingham ,","place":["UK"]},{"name":"Department of Immunology and Immunotherapy, College of Medicine and Health, University of Birmingham , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"2026092605162419800_bib1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2026092605162419800_bib2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0140-6736(23)01736-1","article-title":"Diagnosis and management of ANCA-associated vasculitis","volume":"403","author":"Kronbichler","year":"2024","journal-title":"Lancet"},{"key":"2026092605162419800_bib3","doi-asserted-by":"publisher","first-page":"m1070","DOI":"10.1136\/bmj.m1070","article-title":"ANCA-associated vasculitis","volume":"369","author":"Hunter","year":"2020","journal-title":"BMJ"},{"key":"2026092605162419800_bib4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40620-017-0412-z","article-title":"ANCA-associated vasculitis with renal involvement","volume":"31","author":"Binda","year":"2018","journal-title":"J Nephrol"},{"key":"2026092605162419800_bib5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/ckj\/sfv020","article-title":"The kidneys and ANCA-associated vasculitis: from pathogenesis to diagnosis","volume":"8","author":"Rowaiye","year":"2015","journal-title":"Clin Kidney J"},{"key":"2026092605162419800_bib6","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026092605162419800_bib7","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1093\/ndt\/gfad237","article-title":"ANCA-associated vasculitis: treatment standard","volume":"39","author":"Chalkia","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026092605162419800_bib8","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1056\/NEJM197104292841703","article-title":"Cyclophosphamide therapy in granulomatosis with polyangiitis (Wegener\u2019s)","volume":"284","author":"Novack","year":"1971","journal-title":"N Engl J Med"},{"key":"2026092605162419800_bib9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/rheumatology\/keaf240","article-title":"The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis","volume":"64","author":"Biddle","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026092605162419800_bib10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"2026092605162419800_bib11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"2026092605162419800_bib12","doi-asserted-by":"publisher","first-page":"e26733","DOI":"10.1097\/MD.0000000000026733","article-title":"Cyclophosphamide induction dose and outcomes in ANCA-associated vasculitis with renal involvement","volume":"100","author":"Speer","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2026092605162419800_bib13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40620-015-0208-y","article-title":"Rituximab for treatment of severe renal disease in ANCA-associated vasculitis","volume":"29","author":"Geetha","year":"2016","journal-title":"J Nephrol"},{"key":"2026092605162419800_bib14","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1681\/ASN.2019111197","article-title":"Efficacy of rituximab and plasma exchange in ANCA-associated vasculitis with severe kidney disease","volume":"31","author":"Casal\u00a0Moura","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2026092605162419800_bib15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1681\/ASN.0000000000000274","article-title":"The improved kidney risk score in ANCA-associated vasculitis for clinical practice and trials","volume":"35","author":"Bate","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2026092605162419800_bib16","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/art.40776","article-title":"Effect of disease activity at three and six months after diagnosis on long-term outcomes in ANCA-associated vasculitis","volume":"71","author":"Gopaluni","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026092605162419800_bib17","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.ekir.2019.02.005","article-title":"Estimating the change in renal function during the first year of therapy in ANCA-associated vasculitis","volume":"4","author":"Lepeytre","year":"2019","journal-title":"Kidney Int Rep"},{"key":"2026092605162419800_bib18","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.ekir.2024.02.1431","article-title":"Predictive factors of renal recovery and progression to end-stage kidney disease in patients with ANCA-associated vasculitis and severe kidney disease","volume":"9","author":"Casal\u00a0Moura","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026092605162419800_bib19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12882-019-1226-0","article-title":"Intravenous pulse methylprednisolone for induction of remission in severe ANCA-associated vasculitis","volume":"20","author":"Chanouzas","year":"2019","journal-title":"BMC Nephrol"},{"key":"2026092605162419800_bib20","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"2026092605162419800_bib21","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.42515","article-title":"Comparative effectiveness of rituximab- vs cyclophosphamide-based remission induction strategies in ANCA-associated vasculitis","volume":"75","author":"Wallace","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026092605162419800_bib22","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1681\/ASN.2014010046","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement","volume":"26","author":"Geetha","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2026092605162419800_bib23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/ndt\/gfx378","article-title":"Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal ANCA-associated vasculitis","volume":"34","author":"McAdoo","year":"2019","journal-title":"Nephrol Dial Transplant"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag290\/70942527\/sfag290.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/9\/sfag290\/70942527\/sfag290.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/9\/sfag290\/70942527\/sfag290.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:16:28Z","timestamp":1790414188000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag290\/8781096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag290","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,9,1]]},"article-number":"sfag290"}}